27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Morgan Stanley upgraded Gilead Sciences, Inc. (NASDAQ: GILD) from Equal-weight to Overweight Monday and raised its price target from $100 to $104.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analyst Matthew Harrison felt that price fears were exaggerated. Analysts at Bank of America and Deutsche Bank predicted a possible price war following the decision of Express Scripts to chose AbbVie Inc (NYSE: ABBV) as its exclusive supplier of hepatitis C treatments.
Harrison saw an improved risk-to-reward ratio now that shares have declined and felt the company can maintain a 75 percent market share even with the AbbVie price discounts.
Gilead Sciences, Inc. recently traded at $96.86, up 3.27 percent.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.